Keyphrases
Encorafenib
100%
Breast
100%
Biweekly Cetuximab
100%
Functional Assessment of Cancer Therapy
100%
BRAF V600E
100%
Longitudinal Survey
100%
Phase II Study
100%
Metastatic Colorectal Cancer (mCRC)
100%
Cetuximab
100%
Rehabilitation Needs
75%
Health-related Quality of Life
75%
Targeted Therapy
66%
Cancer Rehabilitation
50%
Breast Cancer Patients
50%
Resistance Mechanisms
33%
Tolerability
33%
Data Collection Time
25%
Rehabilitative Services
25%
Rehabilitation Services
25%
DASH Questionnaire
25%
Copenhagen
25%
Quality of Care
25%
QuickDASH
25%
Functional Status
25%
Patient-reported Outcomes
25%
Upper Body Function
25%
Number of Services
25%
Distress Thermometer
25%
Group-based Exercise
25%
Disabilities of the Arm
25%
Optimal Two-stage Design
16%
Median Progression-free Survival
16%
BRAF Inhibitor (BRAFi)
16%
De-novo mutations
16%
Transcriptomics
16%
Cancer Resistance
16%
EudraCT
16%
Improved Survival
16%
Response Mechanism
16%
Number of Visits
16%
Genetic Modification
16%
New Standards
16%
Median Overall Survival
16%
Epigenetics
16%
Mutation Resistance
16%
Emerging Challenges
16%
DNA Analysis
16%
Comprehensive Genomic Profiling
16%
Tumor Tissue
16%
Progression-free Survival
16%
Nursing and Health Professions
Rehabilitation Engineering
100%
Longitudinal Survey
100%
Cancer Therapy
50%
Functional Assessment
50%
Quality of Life
37%
Breast Cancer
25%
Cancer Rehabilitation
25%
Malignant Neoplasm
12%
Disabilities of the Arm, Shoulder and Hand (Score)
12%
Patient-Reported Outcome
12%
Rehabilitation Center
12%
Functional Status
12%
Patient Referral
12%
Medicine and Dentistry
Rehabilitation Engineering
100%
Functional Assessment
44%
Cancer Therapy
44%
Quality of Life
33%
Breast Cancer
22%
Cancer Rehabilitation
22%
Arm
11%
Patient Referral
11%
Malignant Neoplasm
11%
Disabilities of the Arm, Shoulder and Hand (Score)
11%
Functional Status
11%
Patient-Reported Outcome
11%
